
Orphazyme A/S ORPH
Country |
|
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
20 M |
Market Cap[1] |
$ 31.3 M |
EBITDA (LTM) |
$ 17.6 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Fennec Pharmaceuticals
FENC
|
$ 13.29 | -2.14 % | $ 380 M | Nasdaq Capital Market | ||
|
Cytokinetics, Incorporated
CYTK
|
$ 51.27 | -0.74 % | $ 6.16 M | Nasdaq Global Select Market,SPB | ||
|
Immunome
IMNM
|
$ 16.67 | -2.97 % | $ 1.46 B | Nasdaq Global Select Market | ||
|
Immunic
IMUX
|
$ 7.53 | 2.73 % | $ 1.17 B | Nasdaq Global Select Market | ||
|
Immunovant
IMVT
|
$ 33.18 | -0.09 % | $ 6.05 B | Nasdaq Global Select Market | ||
|
Incyte Corporation
INCY
|
$ 117.79 | -1.09 % | $ 23 B | Nasdaq Global Select Market,SPB | ||
|
Insmed Incorporated
INSM
|
$ 120.17 | -1.39 % | $ 23.9 B | Nasdaq Global Select Market | ||
|
Iovance Biotherapeutics
IOVA
|
$ 7.49 | -0.6 % | $ 2.68 M | Nasdaq Global Market,SPB | ||
|
Dyadic International
DYAI
|
$ 0.32 | 1.27 % | $ 11.6 M | Nasdaq Capital Market | ||
|
Ironwood Pharmaceuticals
IRWD
|
$ 4.79 | -1.75 % | $ 775 M | Nasdaq Global Select Market | ||
|
Fulcrum Therapeutics
FULC
|
$ 3.73 | -0.67 % | $ 284 M | Nasdaq Global Market | ||
|
Johnson & Johnson
JNJ
|
$ 272.65 | -2.17 % | $ 656 B | NYSE,SPB | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 94.99 | -0.13 % | $ 7.05 B | Nasdaq Global Select Market | ||
|
Kazia Therapeutics Limited
KZIA
|
$ 5.44 | 2.45 % | $ 82.9 M | Nasdaq Global Select Market | ||
|
Eli Lilly and Company
LLY
|
$ 1 381.41 | -2.41 % | $ 1.24 T | NYSE,SPB | ||
|
Immuron Limited
IMRN
|
$ 0.87 | -0.51 % | $ 201 M | Nasdaq Global Select Market | ||
|
Mesoblast Limited
MESO
|
$ 11.66 | -2.1 % | $ 14.1 B | Nasdaq Global Select Market | ||
|
Geron Corporation
GERN
|
$ 1.0 | -0.2 % | $ 667 M | Nasdaq Global Select Market | ||
|
Merck & Co.
MRK
|
$ 137.88 | -3.83 % | $ 345 B | NYSE,SPB | ||
|
Genmab A/S
GMAB
|
$ 50.93 | -1.98 % | $ 3.3 B | Nasdaq Global Select Market | ||
|
Moderna
MRNA
|
$ 196.67 | -4.9 % | $ 76.5 B | Nasdaq Global Select Market,SPB | ||
|
Gossamer Bio
GOSS
|
$ 11.37 | 2.99 % | $ 2.6 B | Nasdaq Global Select Market,SPB | ||
|
GeoVax Labs
GOVX
|
$ 1.99 | -1.24 % | $ 9.08 M | Nasdaq Global Select Market | ||
|
Grifols, S.A.
GRFS
|
$ 8.49 | -1.56 % | $ 5.77 B | Nasdaq Global Select Market | ||
|
Mirum Pharmaceuticals
MIRM
|
$ 92.52 | 0.62 % | $ 4.64 B | Nasdaq Global Select Market | ||
|
MediciNova
MNOV
|
$ 1.33 | -0.75 % | $ 65.3 M | Nasdaq Global Market | ||
|
InflaRx N.V.
IFRX
|
$ 1.11 | -3.48 % | $ 74.7 M | Nasdaq Global Select Market | ||
|
INmune Bio
INMB
|
$ 1.02 | 6.25 % | $ 25.3 M | Nasdaq Capital Market | ||
|
Ionis Pharmaceuticals
IONS
|
$ 27.39 | 1.59 % | $ 4.38 B | Nasdaq Global Select Market,SPB | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
$ 246.57 | 2.43 % | $ 15 B | Nasdaq Global Select Market | ||
|
Nektar Therapeutics
NKTR
|
$ 34.77 | -3.17 % | $ 587 M | Nasdaq Global Select Market,SPB | ||
|
Kala Pharmaceuticals
KALA
|
$ 3.31 | -3.5 % | $ 27 M | Nasdaq Global Select Market | ||
|
Novartis AG
NVS
|
$ 155.26 | -2.43 % | $ 301 B | NYSE | ||
|
Omeros Corporation
OMER
|
$ 14.67 | 4.24 % | $ 932 M | Nasdaq Global Select Market | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.84 | 3.54 % | $ 193 M | NYSE American | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
$ 298.84 | 1.71 % | $ 5.78 B | Nasdaq Global Select Market,SPB | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.2 | 4.35 % | $ 54.8 M | Nasdaq Capital Market | ||
|
Mustang Bio
MBIO
|
$ 0.38 | -2.31 % | $ 1.87 M | Nasdaq Global Market | ||
|
Adagene
ADAG
|
$ 1.78 | 20.27 % | $ 105 M | Nasdaq Global Market | ||
|
Puma Biotechnology
PBYI
|
$ 7.22 | 1.12 % | $ 361 M | Nasdaq Global Select Market | ||
|
Denali Therapeutics
DNLI
|
$ 18.41 | 2.25 % | $ 3.18 B | Nasdaq Global Select Market,SPB | ||
|
Amarin Corporation plc
AMRN
|
$ 11.25 | -0.18 % | $ 4.67 B | Nasdaq Global Market | ||
|
ImmuCell Corporation
ICCC
|
$ 11.2 | -1.15 % | $ 101 M | Nasdaq Global Select Market | ||
|
Editas Medicine
EDIT
|
$ 1.77 | -3.29 % | $ 157 M | Nasdaq Global Select Market,SPB | ||
|
Agios Pharmaceuticals
AGIO
|
$ 29.7 | -0.64 % | $ 1.72 B | Nasdaq Global Select Market,SPB | ||
|
Pfizer
PFE
|
$ 28.06 | -1.46 % | $ 159 B | NYSE,SPB | ||
|
NuCana plc
NCNA
|
$ 0.82 | -7.71 % | $ 9.21 B | Nasdaq Global Select Market | ||
|
Equillium
EQ
|
$ 1.1 | -9.5 % | $ 63 M | Nasdaq Global Market | ||
|
Black Diamond Therapeutics
BDTX
|
$ 1.43 | -1.04 % | $ 81.3 M | Nasdaq Global Select Market,SPB | ||
|
Abeona Therapeutics
ABEO
|
$ 2.73 | 4.81 % | $ 145 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.